Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
AstraZeneca ( (GB:AZN) ) has provided an update.
AstraZeneca announced the filing of its 2024 Annual Report on Form 20-F with the US Securities and Exchange Commission, providing stakeholders access to its complete audited financial statements. This filing underscores AstraZeneca’s transparency and commitment to compliance, which can enhance trust among investors and affirm its strong position in the biopharmaceutical industry.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK, focusing on the discovery, development, and commercialization of prescription medicines in areas such as Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its innovative medicines are available in more than 125 countries, reaching millions of patients worldwide.
YTD Price Performance: 11.90%
Average Trading Volume: 2,726,647
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: £181.6B
For detailed information about AZN stock, go to TipRanks’ Stock Analysis page.
